Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients

Documenti analoghi

• Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T‐lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia
  di: Wallace Bourgeois, et al.
  Pubblicazione: (2024)
• Quality of life and family functioning 12 months after diagnosis of childhood brain tumour: A longitudinal cohort study
  di: Kate Young, et al.
  Pubblicazione: (2024)
• FGFR1:TACC1 ‐Fused Pilocytic Astrocytoma in a Child With Muenke Syndrome: A Case Report
  di: Veda Malhotra, et al.
  Pubblicazione: (2026)
• Neuropsychological Performance and Its Predictors in the Early Treatment Phase of Non‐CNS Pediatric Cancer
  di: Marisa H. Huisman, et al.
  Pubblicazione: (2025)
• Chronic spontaneous urticaria as the presenting feature in a paediatric case of chronic myeloid leukaemia
  di: Kathryn M. Sutton, et al.
  Pubblicazione: (2024)